The chemo that cured childhood liver cancer — and the genetic scars it leaves behind

For most of the last four decades, the story of hepatoblastoma — the most common pediatric liver cancer — has been a clean win. Platinum-based chemotherapy, principally cisplatin and, when needed, carboplatin, pushed five-year survival for localized tumors from roughly 20% to more than 80% (STAT News, 2026-09-10). A cancer that once killed four out of five children is now one most of them survive.

A study published [Thursday in Science](https://www.science.org/doi/10.1126/science.ady0339) adds a quieter second chapter to that story. Researchers have, for the first time, counted the mutations these drugs leave behind in the healthy liver tissue of children who were treated and cured. The number is large enough to matter — and structured enough to act on.

Using a method called NanoSeq, a duplex DNA sequencing approach tuned to catch very rare variants, the team compared healthy and tumor liver tissue from children who had received platinum chemotherapy with tissue from children treated with non-platinum regimens and with fetal liver samples. In the platinum-treated livers, they found an average of about 2,200 mutations per sample — a burden normally seen in adult, not pediatric, tissue. The implication is that platinum chemotherapy effectively accelerates the molecular age of liver cells (bioRxiv preprint).

"The fact that we can see this in a normal, healthy part of the liver is striking," said co-author Foad Rouhani of King's College London. "By no means does that mean that these cells will definitely become cancerous in time — these mutations are simply evidence of potential" (STAT News).

The "potential" matters because the mutations did not land randomly. They clustered in known cancer genes and in genes tied to long-term liver metabolism. That is a worry for survivors — and a roadmap for the surveillance that should follow them into adulthood.

Three findings sharpen the picture.

First, the mutational load is dose-responsive. Children who received cisplatin alone carried fewer liver mutations than those who received both cisplatin and carboplatin. The more platinum exposure, the more genetic damage. That gradient is what turns a vague late-effects worry into something oncologists can plan around.

Second, the damage is liver-tropic. Despite chemotherapy being delivered through the bloodstream, liver cells accumulated far more mutations than blood cells. The liver is not just a passive bystander in platinum metabolism; it is the organ that bears the heaviest molecular cost.

Third, the mutations sit in the parts of the genome that matter most. The clustering in cancer genes and metabolic genes is not a generic mutational signature — it is a map of where future risk is most likely to surface.

A perspective accompanying the paper from Vasudevan and Parsons at Baylor frames the result as the first rigorous, tissue-level accounting of platinum's long shadow in children. The technique, NanoSeq, deserves a brief mention: it sequences both strands of a DNA duplex to filter out the sequencing errors that usually obscure low-frequency mutations, which is why a measurement that would have been impossible a decade ago is now precise enough to compare across patients.

The honest read is that this is not a case against platinum chemotherapy. Without it, four out of five children with localized hepatoblastoma would not have survived. The new finding is the cost side of a ledger that previously only showed the credit column, and it gives survivors, families, and oncologists a basis to think about cumulative platinum exposure and lifelong liver monitoring that did not exist before the measurement existed.

Rouhani's framing is the right one to close on: the mutations are evidence of potential, not a sentence. "These mutations are simply evidence of potential," he told STAT. The next step is converting that potential into a surveillance protocol — and into gentler platinum-sparing regimens for the children still to come.

The team has not yet measured whether the children in the cohort go on to develop secondary liver tumors or liver disease at rates higher than their peers. That decades-scale follow-up is the watch item. What is already in hand, as of this week, is a number: roughly 2,200 mutations, in the places that matter, scaling with the dose that saved them.